Keybanc Maintains Overweight on Castle Biosciences, Raises Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
Keybanc analyst Paul Knight has maintained an Overweight rating on Castle Biosciences (NASDAQ:CSTL) and increased the price target from $25 to $28.
March 01, 2024 | 8:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Castle Biosciences maintains an Overweight rating by Keybanc with an increased price target from $25 to $28.
The increase in price target by a reputable analyst like Paul Knight suggests a positive outlook on Castle Biosciences' stock, likely leading to increased investor confidence and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100